A new space in the immunotherapy market

Spin-off from the Pasteur Institute, DIACCURATE is opening a new space in the booming market segment of immunotherapy: trans CD4 immunotherapy. By blocking a molecular mechanism leading to CD4 anergy, DIACCURATE aims to restore the CD4 T-cells’ ability to fight microbial infections and cancers.


Today DIACCURATE is conducting proprietary development programs in disease indications with partial or total CD4 immunodeficiency. A phase I/II multi-center trial is already planned in HIV for the most advanced product of the company, the anti-PLA2G1B enzyme drug candidate; a “sole in class antibody” that could achieve for the very first time the functional cure of HIV patients.


DIACCURATE was founded by Prof. Jacques THÈZE, an international leading authority in the fields of CD4 biology and HIV infection and its former student, Dr. Philippe POULETTY, who since then has pioneered the development of biotechnology and co-founded Truffle Capital of which he is now the Life Science General Manager. 


Based in Paris, France, at the Pasteur Institute, the company is supported by an experienced management team and a world class academic network committed to make CD4 trans immunotherapy a new therapeutic standard in infections and cancers.



Prof. Jacques THÈZE, MD, PhD, CEO, CSO

Dr. Philippe POULETTY, MD, Chairman

  • Former Prof and Head dpt Human Immunology at Institut Pasteur

  • Post doc fellow Harvard Medical School (B. Benacerraf)

  • > 250 scientific and medical publications

  • WHO adviser “New vaccine program”

  • Sanofi Co. adviser ” Cytokines and immunotherapy program”

  • Corresponding member of the French National Academy of Medicine


  • Co-founder & Life Science General Manager of Truffle Capital

  • Postdoctoral fellow Stanford University

  • SangStat co-founder (acquired by Genzyme $600 million)

  • 29 patents in biotechnology

  • Member of the board of directors of 12 European biotechs and medtechs

  • Honorary President & founder of France Biotech

  • Former Vice-President of EuropaBio


Leadership team



Deputy CEO and CFO

  • CFO at Vexim

  • Former Head of Finance at Cloudwatt


Dr. Jean Pierre ROUTY, MD

Senior Consultant Clinical

  • Professor and Research, Director at McGill University Health Centre



Senior Consultant Development

  • Chairman of OFU

  • Former EVP & Chief Dev. Officer at Innate Pharma (2001-2018)

Bernard MALISSEN, PhD, Senior Consultant Scientific Affairs

  • Director of CIPHE

  • Member of the French Academy of Science


Scientific Board


Prof. Luc TEYTON, MD, PhD


Professor in the Department of Immunology and Microbiology at the Scripps Research Institute (La Jolla, California, USA)

Prof. Hervé WATIER, MD, PhD

Professor of Immunology at the Faculty of Medicine in Tours (France)
Head of the Immunology Department of the University Hospital in Tours
Supervisor of the MAbImprove Labex
Director the “Ambition Research & Development 2020 Biopharmceuticals” program


Prof. José ALCAMI, MD, PhD

Head of the AIDS Immuno-pathogenesis Unit (IPlab) at the National Research Center of the Instituto de Salud Carlos III (Madrid, Spain)
Scientific Director of the HIV Unit at Hospital Clinic (Barcelona, Spain)
Coordinator of the Spanish AIDS Research Network

Dr Gérard LAMBEAU, PhD

Head of the team "Physiopathology of Phospholipases A2 and their Mediators" at the Institute of Molecular and Cellular Pharmacology (IPMC) in Sophia-Antipolis (Valbonne, France)

Download the press release announcing the composition of our Scientific Advisory Board


A Pasteur Institute’s heritage

From the identification of the etiologic agent of AIDS to the discovery of blood molecular driver of CD4 immunodeficiency, Diaccurate is the fruit of over 30 years of research and innovation done by the Pasteur Institute in Paris.

Contact Us

Phone: 33 1 45 68 86 00

Fax: 33 1 45 68 88 38

  • Twitter - Cercle blanc
  • LinkedIn


3-5 impasse Reille

75014 Paris, France

© 2019 DIACCURATE with ATCG Partners